News and Trends 23 Jun 2023 SandboxAQ launches new division to boost drug development …diseases are enormously complex and defy standard drug design,” said Stanley B. Prusiner, who leads the UCSF Institute for Neurodegenerative Diseases. “We need rational and structure-based design methods that can… June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Nov 2025 Eight CAR-T cell therapy companies you should know about …to create CAR-T therapies specifically tuned to address autoimmune diseases. Its lead candidate CABA-201, is a fully human CD19-CAR T cell therapy, which is in early stages of clinical trials for systemic… November 19, 2025 - 16 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Everest Medicines gets go-ahead for renal disease drug study …of EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned phase 1b clinical study will evaluate the safety, efficacy,… September 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus …Sanofi answered some questions from Labiotech.eu about the news for our in-depth newsletter on children’s diseases. When it came to finding a solution, what were the steps involved, and how… November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 The challenges of tackling dementia in women …comes to addressing women’s health. Dementia is a leading cause of death in women, but it doesn’t get the attention of other diseases, such as breast cancer. Why do you… March 8, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2019 Rapid Response mRNA Vaccine Facility Gets €30M Funding …emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates deliver mRNA molecules to cells… March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Kupando raises €13M in series A funding round led by Remiges Ventures …immunity for use in oncology and infectious diseases. Kupando says it will use the funds to complete IND-enabling work and to initiate the clinical development its lead candidate, KUP101 in… September 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2024 Six biotech companies advancing multiple sclerosis therapies …its potential to treat autoimmune disorders, too. This is what Kyverna Therapeutics is focusing on, as it is attempting to develop cell therapies for patients suffering from B-cell-driven autoimmune diseases…. October 24, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine …diseases associated with EBV. EBV is the causative agent of infectious mononucleosis and is associated with certain malignancies and autoimmune diseases, such as nasopharyngeal carcinoma, gastric cancer, Hodgkin’s Lymphoma, Burkitt’s… August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2025 First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? …battling infectious diseases? Table of contents Roche’s antibiotic zosurabalpin to enter phase 3 trials Swiss drug maker Roche hit the headlines when it announced that it is advancing the development… June 9, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Jan 2019 5 Real-Life Technologies Where Biotech Meets Science Fiction …world routinely modify the DNA of worms, fruit flies, zebrafish, mice, and many others to replicate and study human diseases. Genetically modified mosquitoes are being used to prevent the spread… January 28, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it …series C round led by Novo Holdings. Asceneuron is focused on developing therapeutics for neurodegenerative diseases and the funds will accelerate the development of their lead asset, ASN51, a promising… July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email